DOCSLIB.ORG

Management of Acute Otitis Media: Update

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Management of Acute Otitis Media: Update Evidence Report/Technology Assessment Number 198 Management of Acute Otitis Media: Update Prepared for: Agency for Healthcare Research and Quality U.S. Department of Health and Human Services 540 Gaither Road Rockville, MD 20850 www.ahrq.gov Contract No. HHSA 290-2007-10056-I Prepared by: RAND Corporation, Santa Monica, CA 90407 Investigators Paul G. Shekelle, M.D., Ph.D. Glenn Takata, M.D., M.S. Sydne J. Newberry, Ph.D. Tumaini Coker, M.D. Mary Ann Limbos, M.D., M.P.H. Linda S. Chan, Ph.D. Martha M. Timmer, M.S. Marika J. Suttorp, M.S. Jason Carter, B.A. Aneesa Motala, B.A. Di Valentine, J.D. Breanne Johnsen, B.A. Roberta Shanman, M.L.S. AHRQ Publication No. 11-E004 November 2010 This report is based on research conducted by the RAND Evidence-based Practice Center (EPC) under contract to the Agency for Healthcare Research and Quality (AHRQ), Rockville, MD (Contract No. HHSA 290-2007-10056-I). The findings and conclusions in this document are those of the author(s), who are responsible for its content, and do not necessarily represent the views of AHRQ. No statement in this report should be construed as an official position of AHRQ or of the U.S. Department of Health and Human Services. The information in this report is intended to help clinicians, employers, policymakers, and others make informed decisions about the provision of health care services. This report is intended as a reference and not as a substitute for clinical judgment. This report may be used, in whole or in part, as the basis for the development of clinical practice guidelines and other quality enhancement tools, or as a basis for reimbursement and coverage policies. AHRQ or U.S. Department of Health and Human Services endorsement of such derivative products may not be stated or implied. This document is in the public domain and may be used and reprinted without permission except those copyrighted materials noted for which further reproduction is prohibited without the specific permission of copyright holders. Suggested Citation: Shekelle PG, Takata G, Newberry SJ, Coker T, Limbos M, Chan LS, Timmer M, Suttorp M, Carter J, Motala A, Valentine D, Johnsen B, Shanman R. Management of Acute Otitis Media: Update. Evidence Report/Technology Assessment No. 198. (Prepared by the RAND Evidence-Based Practice Center under Contract No. 290 2007 10056 I). Rockville, MD: Agency for Healthcare Research and Quality. November 2010. No investigators have any affiliations or financial involvement (e.g., employment, consultancies, honoraria, stock options, expert testimony, grants or patents received or pending, or royalties) that conflict with material presented in this report. ii Preface The Agency for Healthcare Research and Quality (AHRQ), through its Evidence-Based Practice Centers (EPCs), sponsors the development of evidence reports and technology assessments to assist public- and private-sector organizations in their efforts to improve the quality of health care in the United States. This report was requested by the American Academy of Pediatrics (AAP). The reports and assessments provide organizations with comprehensive, science-based information on common, costly medical conditions and new health care technologies. The EPCs systematically review the relevant scientific literature on topics assigned to them by AHRQ and conduct additional analyses when appropriate prior to developing their reports and assessments. To bring the broadest range of experts into the development of evidence reports and health technology assessments, AHRQ encourages the EPCs to form partnerships and enter into collaborations with other medical and research organizations. The EPCs work with these partner organizations to ensure that the evidence reports and technology assessments they produce will become building blocks for health care quality improvement projects throughout the Nation. The reports undergo peer review prior to their release. AHRQ expects that the EPC evidence reports and technology assessments will inform individual health plans, providers, and purchasers as well as the health care system as a whole by providing important information to help improve health care quality. We welcome comments on this evidence report. They may be sent by mail to the Task Order Officer named below at: Agency for Healthcare Research and Quality, 540 Gaither Road, Rockville, MD 20850, or by e-mail to [email protected]. Carolyn M. Clancy, M.D. Jean Slutsky, P.A., M.S.P.H. Director Director, Center for Outcomes and Evidence Agency for Healthcare Research and Quality Agency for Healthcare Research and Quality Stephanie Chang, M.D., M.P.H. CAPT Ernestine Murray, R.N., B.S.N., M.A.S. Director, EPC Program EPC Program Task Order Officer Agency for Healthcare Research and Quality Agency for Healthcare Research and Quality iii Acknowledgments We wish to acknowledge the invaluable guidance and expertise contributed to this project by the Technical Expert Panel members who are listed in Appendix F. We also thank CAPT Ernestine (Tina) Murray (AHRQ) for her patience, guidance, and input, and the Oregon Evidence-based Practice Center, Rose Relevo, for assistance with research on drug safety, and the administrative staff for assistance with preparation of the report. iv Structured Abstract Context: Acute Otitis Media (AOM), a viral or bacterial infection of the ear, is the most common childhood infection for which antibiotics are prescribed in the United States. In 2001, the Southern California Evidence-based Practice Center conducted a systematic review of the evidence comparing treatments of AOM. Objectives: This review updates the 2001 review findings on diagnosis and treatment of uncomplicated AOM, assesses the evidence for treatment of recurrent AOM, and assesses the impact of the heptavalent pneumococcal conjugate (PCV7) vaccine on the microbiology of AOM. Data Sources and Study Selection: Searches of PubMed and the Cochrane databases were conducted from January 1998 July 2010 using the same search strategies used for the 2001 report, with the addition of terms not considered in the 2001 review. The Web of Science was also searched for citations of the 2001 report and its peer-reviewed publications. Data Extraction: After review by two investigators against pre-determined inclusion/exclusion criteria, we included existing systematic reviews and randomized controlled clinical trials for assessment of treatment efficacy and safety. Pooled analysis was performed for comparisons with three or more trials. Results and Conclusions: Few studies were found that examined the accuracy and precision of the diagnosis of AOM. Since PCV7’s introduction, AOM microbiology has shifted significantly, with Streptococcus pneumoniae becoming less prevalent and Haemophilus influenzae (HF) increasing in importance. For uncomplicated AOM, pooled analysis indicates that nine children (95% CI: 6, 20) would need to be treated with ampicillin or amoxicillin rather than placebo to note a difference in the rate of clinical success. However, in four studies of delayed treatment approaches for uncomplicated AOM, two had higher rates of clinical success with immediate antibiotic therapy while two did not, and in three studies, a marked decrease in antibiotic utilization was noted. We are unable to draw definitive conclusions regarding the comparative effectiveness of different antibiotics for AOM in children with recurrent otitis media (ROM). For ROM, long-term antibiotic administration will decrease AOM episodes from 3 to 1.5 for every 12 months of treatment per otitis prone child during active treatment (95% CI: 1.2, 2.1); however, potential consequences of long-term treatment need to be considered. Data were insufficient to draw conclusions about comparative effectiveness of different treatment strategies in subgroups of children with uncomplicated AOM. Adverse events were generally more frequent for amoxicillin-clavulanate than for cefdinir, ceftriaxone, or azithromycin. Higher quality studies and improved reporting of study characteristics related to quality are needed to provide definitive conclusions for AOM and ROM treatment options. v vi Contents Executive Summary.........................................................................................................................1 Evidence Report.............................................................................................................................19 Chapter 1. Introduction ..................................................................................................................21 Diagnostic Accuracy..............................................................................................................21 Management...........................................................................................................................21 Pneumococcal Conjugate Vaccine.........................................................................................22 Chapter 2. Methods.......................................................................................................................23 Original Proposed Key Questions.............................................................................................23 Technical Expert Panel .............................................................................................................24 Definitions of Acute Otitis Media.............................................................................................24 Literature Search.......................................................................................................................25
Load more

Recommended publications
  • List of Union Reference Dates A
    Active substance name (INN) EU DLP BfArM / BAH DLP yearly PSUR 6-month-PSUR yearly PSUR bis DLP (List of Union PSUR Submission Reference Dates and Frequency (List of Union Frequency of Reference Dates and submission of Periodic Frequency of submission of Safety Update Reports, Periodic Safety Update 30 Nov. 2012) Reports, 30 Nov.
    [Show full text]
  • Product Information
    ATROPINE INJECTION BP (Atropine sulfate monohydrate) 1. NAME OF THE MEDICINE Atropine sulfate monohydrate 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Atropine Injection BP is a sterile, isotonic, preservative free solution containing 600 microgram of atropine sulfate monohydrate in 1 mL or 1.2 mg of atropine sulfate monohydrate in 1 mL. 3. PHARMACEUTICAL FORM Solution for injection 4. CLINICAL PARTICULARS 4.1 Therapeutic Indications Preanaesthetic medication to reduce salivary secretions and bronchial secretions to prevent cholinergic cardiac effects such as cardiac arrhythmias, hypotension and bradycardia management of patients with acute myocardial infarction and sinus bradycardia who have associated hypotension and increased ventricular irritability concurrent administration with anticholinesterase agents (e.g. neostigmine, physostigmine) to block the adverse muscarinic effects of these agents following surgery to terminate curarisation for poisoning by organophosphate pesticides, atropine may be used concomitantly with a cholinesterase reactivator such as pralidoxime to reverse muscarinic effects. 4.2 Dose and Method of Administration Atropine Injection may be given by subcutaneous (SC), intramuscular (IM) or direct intravenous (IV) injection. Atropine Injection should not be added to any IV infusion solutions for administration. Atropine Injection contains no microbial agent. It should be used only once and any residue discarded. Cardiopulmonary resuscitation The usual adult dose is 0.4 - 1 mg IV, which may be repeated at 5 minute intervals until the desired heart rate is achieved. The total dose should not exceed 2 mg. Page 1 of 11 The usual paediatric dose is 0.02 mg/kg (maximum single dose 0.5 mg) IV, which may be repeated at 5 minute intervals until the desired heart rate is achieved.
    [Show full text]
  • Tympanostomy Tubes in Children Final Evidence Report: Appendices
    Health Technology Assessment Tympanostomy Tubes in Children Final Evidence Report: Appendices October 16, 2015 Health Technology Assessment Program (HTA) Washington State Health Care Authority PO Box 42712 Olympia, WA 98504-2712 (360) 725-5126 www.hca.wa.gov/hta/ [email protected] Tympanostomy Tubes Provided by: Spectrum Research, Inc. Final Report APPENDICES October 16, 2015 WA – Health Technology Assessment October 16, 2015 Table of Contents Appendices Appendix A. Algorithm for Article Selection ................................................................................................. 1 Appendix B. Search Strategies ...................................................................................................................... 2 Appendix C. Excluded Articles ....................................................................................................................... 4 Appendix D. Class of Evidence, Strength of Evidence, and QHES Determination ........................................ 9 Appendix E. Study quality: CoE and QHES evaluation ................................................................................ 13 Appendix F. Study characteristics ............................................................................................................... 20 Appendix G. Results Tables for Key Question 1 (Efficacy and Effectiveness) ............................................. 39 Appendix H. Results Tables for Key Question 2 (Safety) ............................................................................
    [Show full text]
  • Chronic Otitis Media: Histopathological Changes a Post Mortem Study on Temporal Bones
    European Review for Medical and Pharmacological Sciences 1999; 3: 175-178 Chronic otitis media: histopathological changes A post mortem study on temporal bones F. SALVINELLI, M. TRIVELLI, F. GRECO, F.H. LINTHICUM JR* Institute of Otolaryngology, “Campus Bio-Medico” University - Rome (Italy) *Department of Histopathology, “House Ear Institute” - Los Angeles, CA (USA) Abstract. – The temporal bones of 4 Materials and Methods deceased individuals, with concomitant chronic otitis media are studied. The various histopathological changes in the middle ear We have studied the histopathological cleft are examined: suppuration, polyps, changes in temporal bones of 4 deceased in- granulation tissue. The possibilities of spon- dividuals, with concomitant chronic OM. taneous healing of a perforated TM and the These patients were donors and agreed indications of surgical treatment are dis- during their life to donate post mortem their cussed. temporal bones to the House Ear Institute as Key Words: a contribution to a better knowledge of tem- Temporal bone, Middle ear, Infection, Chronic in- poral bone diseases. flammation, Metaplasia, Complications. We have removed the temporal bones in our usual way9. Introduction Results Otitis media (OM) is an infection localized Clinical features in the middle ear: mastoid, middle ear cavity, The inflammation, while often indolent, eustachian tube. The classification of OM in- may at times give rise to serious complica- cludes: tions and even cause death. The hearing loss that is a constant concomitant also con- tributes to the immense socio-economic problem. Chronic OM sometimes, but not al- • OM with effusion1-3, without perforation ways, follows an attack of the acute disease. of the tympanic membrane (TM)4-6, due The major feature is discharge from the mid- to an increase of fluid in the middle ear dle ear.
    [Show full text]
  • Inner Ear Infection (Otitis Interna) in Dogs
    Hurricane Harvey Client Education Kit Inner Ear Infection (Otitis Interna) in Dogs My dog has just been diagnosed with an inner ear infection. What is this? Inflammation of the inner ear is called otitis interna, and it is most often caused by an infection. The infectious agent is most commonly bacterial, although yeast and fungus can also be implicated in an inner ear infection. If your dog has ear mites in the external ear canal, this can ultimately cause a problem in the inner ear and pose a greater risk for a bacterial infection. Similarly, inner ear infections may develop if disease exists in one ear canal or when a benign polyp is growing from the middle ear. A foreign object, such as grass seed, may also set the stage for bacterial infection in the inner ear. Are some dogs more susceptible to inner ear infection? Dogs with long, heavy ears seem to be predisposed to chronic ear infections that ultimately lead to otitis interna. Spaniel breeds, such as the Cocker spaniel, and hound breeds, such as the bloodhound and basset hound, are the most commonly affected breeds. Regardless of breed, any dog with a chronic ear infection that is difficult to control may develop otitis interna if the eardrum (tympanic membrane) is damaged as it allows bacteria to migrate down into the inner ear. "Dogs with long, heavy ears seem to bepredisposed to chronic ear infections that ultimately lead to otitis interna." Excessively vigorous cleaning of an infected external ear canal can sometimes cause otitis interna. Some ear cleansers are irritating to the middle and inner ear and can cause signs of otitis interna if the eardrum is damaged and allows some of the solution to penetrate too deeply.
    [Show full text]
  • Etats Rapides
    List of European Pharmacopoeia Reference Standards Effective from 2015/12/24 Order Reference Standard Batch n° Quantity Sale Information Monograph Leaflet Storage Price Code per vial Unit Y0001756 Exemestane for system suitability 1 10 mg 1 2766 Yes +5°C ± 3°C 79 ! Y0001561 Abacavir sulfate 1 20 mg 1 2589 Yes +5°C ± 3°C 79 ! Y0001552 Abacavir for peak identification 1 10 mg 1 2589 Yes +5°C ± 3°C 79 ! Y0001551 Abacavir for system suitability 1 10 mg 1 2589 Yes +5°C ± 3°C 79 ! Y0000055 Acamprosate calcium - reference spectrum 1 n/a 1 1585 79 ! Y0000116 Acamprosate impurity A 1 50 mg 1 3-aminopropane-1-sulphonic acid 1585 Yes +5°C ± 3°C 79 ! Y0000500 Acarbose 3 100 mg 1 See leaflet ; Batch 2 is valid until 31 August 2015 2089 Yes +5°C ± 3°C 79 ! Y0000354 Acarbose for identification 1 10 mg 1 2089 Yes +5°C ± 3°C 79 ! Y0000427 Acarbose for peak identification 3 20 mg 1 Batch 2 is valid until 31 January 2015 2089 Yes +5°C ± 3°C 79 ! A0040000 Acebutolol hydrochloride 1 50 mg 1 0871 Yes +5°C ± 3°C 79 ! Y0000359 Acebutolol impurity B 2 10 mg 1 -[3-acetyl-4-[(2RS)-2-hydroxy-3-[(1-methylethyl)amino] propoxy]phenyl] 0871 Yes +5°C ± 3°C 79 ! acetamide (diacetolol) Y0000127 Acebutolol impurity C 1 20 mg 1 N-(3-acetyl-4-hydroxyphenyl)butanamide 0871 Yes +5°C ± 3°C 79 ! Y0000128 Acebutolol impurity I 2 0.004 mg 1 N-[3-acetyl-4-[(2RS)-3-(ethylamino)-2-hydroxypropoxy]phenyl] 0871 Yes +5°C ± 3°C 79 ! butanamide Y0000056 Aceclofenac - reference spectrum 1 n/a 1 1281 79 ! Y0000085 Aceclofenac impurity F 2 15 mg 1 benzyl[[[2-[(2,6-dichlorophenyl)amino]phenyl]acetyl]oxy]acetate
    [Show full text]
  • Inner Ear Fibrocytes This Information Is Current As of October 1, 2021
    ERK2-Dependent Activation of c-Jun Is Required for Nontypeable Haemophilus influenzae-Induced CXCL2 Upregulation in Inner Ear Fibrocytes This information is current as of October 1, 2021. Sejo Oh, Jeong-Im Woo, David J. Lim and Sung K. Moon J Immunol published online 29 February 2012 http://www.jimmunol.org/content/early/2012/02/29/jimmun ol.1103182 Downloaded from Supplementary http://www.jimmunol.org/content/suppl/2012/02/29/jimmunol.110318 Material 2.DC1 http://www.jimmunol.org/ Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication by guest on October 1, 2021 *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2012 by The American Association of Immunologists, Inc. All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. Published February 29, 2012, doi:10.4049/jimmunol.1103182 The Journal of Immunology ERK2-Dependent Activation of c-Jun Is Required for Nontypeable Haemophilus influenzae-Induced CXCL2 Upregulation in Inner Ear Fibrocytes Sejo Oh,*,1 Jeong-Im Woo,*,1 David J. Lim,*,† and Sung K. Moon* The inner ear, composed of the cochlea and the vestibule, is a specialized sensory organ for hearing and balance.
    [Show full text]
  • Clinical Review Otitis Media
    Clinical Review Otitis Media Jack Froom, MD Stony Brook, New York The spectrum of otitis media includes acute and chronic forms, each of which can be either suppurative of nonsuppurative. In the usual clinical setting distinctions between these several forms can be difficult. Determination of accurate incidence fig­ ures is impeded by the unavailability of universally accepted diagnostic criteria. Risk factors include season of the year, genetic factors, race, preceding respiratory tract infections, cleft palate, and others. The effect of household size and al­ lergy are uncertain. The most common infecting organisms are Streptococcus pneumoniae and Hemophilus influenzae, al­ though in a significant number of cases either the fluid is non- pathogenic or no organisms can be isolated. The effects of several therapies are reviewed, including antibiotics, myrin­ gotomy, steroids, and middle-ear ventilating tubes. Otitis media is one of the most frequent condi­ Incidence tions treated by family physicians and pediatricians. Otitis media ranks as the ninth most frequently Yet there are no standard criteria for diagnosis, made diagnosis for all ambulatory patient visits. In artd several issues regarding therapy are contro­ 1977 it accounted for approximately 11 million vis­ versial. The use of antihistamines, decongestants, its to physicians in the United States.1 For approx­ myringotomy, and even antibiotics are matters of imately one half of these visits the problem was contention, and the current roles of tympanometry new. Although these data give some indication of and tympanostomy tubes need clarification. The the ubiquitous nature of the problem, they do not purpose of this paper is to provide recommenda­ permit calculation of annual incidence by age and tions for diagnosis and management based on re­ sex.
    [Show full text]
  • Otitis Media and Interna
    Otitis Media and Interna (Inflammation of the Middle Ear and Inner Ear) Basics OVERVIEW • Inflammation of the middle ear (known as “otitis media”) and inner ear (known as “otitis interna”), most commonly caused by bacterial infection SIGNALMENT/DESCRIPTION OF PET Species • Dogs • Cats Breed Predilections • Cocker spaniels and other long-eared breeds • Poodles with long-term (chronic) inflammation of the ears (known as “otitis”) or the throat (known as “pharyngitis”) associated with dental disease • Primary secretory otitis media (PSOM) is described in Cavalier King Charles spaniels SIGNS/OBSERVED CHANGES IN THE PET • Depend on severity and extent of the infection; range from no signs, to those related to middle ear discomfort and nervous system involvement • Pain when opening the mouth; reluctance to chew; shaking the head; pawing at the affected ear • Head tilt • Pet may lean, veer, or roll toward the side or direction of the affected ear • Pet's sense of balance may be altered (known as “vestibular deficits”)—persistent, transient or episodic • Involvement of both ears—wide movements of the head, swinging back and forth; wobbly or incoordinated movement of the body (known as “truncal ataxia”), and possible deafness • Vomiting and nausea—may occur during the sudden (acute) phase • Facial nerve damage—the “facial nerve” goes to the muscles of the face, where it controls movement and expression, as well as to the tongue, where it is involved in the sensation of taste; signs of facial nerve damage include saliva and food dropping from the
    [Show full text]
  • Drug Control in the Americas
    SEMINAR ON DRUG CONTROL IN THE AMERICAS PAN AMERICAN HEALTH ORGANIZATION Pan American Sanitary Bureau, Regional Office of the WORLD HEALTH ORGANIZATION 1971 SEMINAR ON DRUG CONTROL IN THE AMERICAS (Maracay, Venezuela, 15-20 November 1970) Scientific Publication No. 225 PAN AMERICAN HEALTH ORGANIZATION Pan American Sanitary Bureau, Regional Office of the WORLD HEALTH ORGANIZATION 525 Twenty-Third Street, N.W. Washington, D.C. 20037, U.S.A. 1971 CONTENTS Introduction ...................................................... v Statement by the Minister of Health and Social Welfare of Venezuela, Dr. J. J. Mays Lyon ............................................ 3 Statement by the Chief of the Office of International Public Health, Minis- try of Health and Social Welfare of Venezuela, Dr. Daniel Orellana . .. 5 Statement by the Director of the Pan American Sanitary Bureau, Dr. Abraham Horwitz ........................................... 7 SEMINAR REPORT Recommendations ................................................. 13 Acknowledgment .................................................. 15 Vote of Thanks ................................................... 15 Annex 1: Basic Requirements for the Registration Application for a Drug .......................................................... 16 Annex 2: Recommendation 5 (Chapter XIV) of the Final Report of the Special Meeting of Ministers of Health of the Americas .............. 17 WORKING DOCUMENTS The Present Drug Control Situation in the Countries of the Region- M orris L. Yakowitz ...........................................
    [Show full text]
  • An EANM Procedural Guideline
    European Journal of Nuclear Medicine and Molecular Imaging https://doi.org/10.1007/s00259-018-4052-x GUIDELINES Clinical indications, image acquisition and data interpretation for white blood cells and anti-granulocyte monoclonal antibody scintigraphy: an EANM procedural guideline A. Signore1 & F. Jamar2 & O. Israel3 & J. Buscombe4 & J. Martin-Comin5 & E. Lazzeri6 Received: 27 April 2018 /Accepted: 6 May 2018 # The Author(s) 2018 Abstract Introduction Radiolabelled autologous white blood cells (WBC) scintigraphy is being standardized all over the world to ensure high quality, specificity and reproducibility. Similarly, in many European countries radiolabelled anti-granulocyte antibodies (anti-G-mAb) are used instead of WBC with high diagnostic accuracy. The EANM Inflammation & Infection Committee is deeply involved in this process of standardization as a primary goal of the group. Aim The main aim of this guideline is to support and promote good clinical practice despite the complex environment of a national health care system with its ethical, economic and legal aspects that must also be taken into consideration. Method After the standardization of the WBC labelling procedure (already published), a group of experts from the EANM Infection & Inflammation Committee developed and validated these guidelines based on published evidences. Results Here we describe image acquisition protocols, image display procedures and image analyses as well as image interpre- tation criteria for the use of radiolabelled WBC and monoclonal antigranulocyte antibodies. Clinical application for WBC and anti-G-mAb scintigraphy is also described. Conclusions These guidelines should be applied by all nuclear medicine centers in favor of a highly reproducible standardized practice. Keywords Infection .
    [Show full text]
  • Chronic Otitis Media Is Initiated by a Bulla Cavitation Defect in The
    Edinburgh Research Explorer Chronic otitis media is initiated by a bulla cavitation defect in the FBXO11 mouse model Citation for published version: Del-Pozo, J, Macintyre, N, Azar , A, Glover, J, Milne, E & Cheeseman, M 2019, 'Chronic otitis media is initiated by a bulla cavitation defect in the FBXO11 mouse model', Disease Models and Mechanisms, vol. 12, dmm038315, pp. 1-10. https://doi.org/10.1242/dmm.038315 Digital Object Identifier (DOI): 10.1242/dmm.038315 Link: Link to publication record in Edinburgh Research Explorer Document Version: Publisher's PDF, also known as Version of record Published In: Disease Models and Mechanisms Publisher Rights Statement: This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution and reproduction in any medium provided that the original work is properly attributed General rights Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights. Take down policy The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact [email protected] providing details, and we will remove access to the work immediately and investigate your claim. Download date: 07. Oct. 2021 © 2019. Published by The Company of Biologists Ltd | Disease Models & Mechanisms (2019) 12, dmm038315.
    [Show full text]